Clinical Pharmacology Studies. Phase 1
Abstract
In this report we summarize the work on four different oral formulations of pyridostigmine. We believe that our familiarity with the pharmacokinetics and pharmacodynamics of pyridostigmine has enhanced the validity of our observations. We also describe a study of the safety and tolerance of multiple once-daily doses of WR 6026 in a placebo-controlled, double-blind study. We are convinced that this study design was essential for correctly interpreting symptoms and abnormalities of laboratory tests that would have been impossible without a placebo control group. Keywords: Antimalarials.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 21, 1989
- Accession Number
- ADA210900
Entities
People
- Brent G. Petty
- David M. Kornhauser
- Paul S. Lietman
Organizations
- Johns Hopkins University